Skip to main content
. 2019 Dec 31;9(1):102. doi: 10.3390/jcm9010102

Figure 3.

Figure 3

Kaplan–Meier survival curves for progression-free survival (PFS) of patients who received immune checkpoint inhibitor (ICI) rechallenge treatment. (a) Eastern Cooperative Oncology Group (ECOG-PS) ≥ 2, (b) body mass index (BMI) ≤ 20, (c) neutrophil-to-lymphocyte ratio (NLR) > 5, and (d) lymphocyte-to-monocyte ratio (LMR) ≤ 1.7 were significantly associated with inferior PFS.